Gynecologic Oncology

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

The addition of anlotinib to sintilimab appeared to be efficacious and safe when used as a second- or later-line treatment in patients with PD-L1–positive, recurrent or metastatic cervical cancer.

Drs Bradley Monk and David O’Malley explain dose reduction in endometrial carcinoma treatment based on clinical trial data.

Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.

An overview of biomarker testing in endometrial carcinoma.

Oncologists describe a typical presentation of endometrial carcinoma and debate the implications of radiation treatment.

The addition of carboplatin to paclitaxel prolonged overall survival and progression-free survival, and proved to be noninferior to the standard combination of paclitaxel and ifosfamide in patients with uterine carcinosarcoma.

"If you stay at home too long, with too narrow a focus, you lose sight of what’s happening in the world."

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Regeneron Pharmaceuticals, Inc. and Sanofi announced the voluntarily withdrawal of the supplemental biologics license application for cemiplimab-rwlc as a second-line treatment for patients with advanced cervical cancer whose disease progressed on or after chemotherapy.

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival rate is just 17%.

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.

Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of pembrolizumab plus lenvatinib for use in patients with unresectable, advanced, or recurrent endometrial carcinoma that has progressed on chemotherapy.

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.